← Leaderboards
Murray B. Stein
University Of California, San Diego
$36,454,107
Attributed
$64,045,670
Total exposure
17
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.5M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$64,045,670 · 16
VA$0 · 1
By mechanism
U01$48,342,435 · 2
R01$12,390,418 · 6
K24$1,340,971 · 1
R61$1,099,216 · 1
R21$868,395 · 2
M01$4,234 · 3
Top collaborators
- Karestan C Koenen8 shared
- Caroline M Nievergelt8 shared
- Kerry J. Ressler8 shared
- Joel Gelernter6 shared
- Robert J. Ursano5 shared
- Joan R. Kaufman3 shared
- Charles Taylor2 shared
- Martin P Paulus1 shared
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseResearch PersonnelAnxietyBaseSamplingProgramsHuman SubjectGenotypeGenesAnxiety DisordersVariantSymptomsClinical ResearchGeneticGenomicsTraitComorbidityFutureGenome-WideLinkDiagnosisPost-Traumatic Stress DisordersCollaborationsNeurobiology
Grant awards (85)
Expanding Genetic Understanding of Depression, Anxiety, and their Treatments$581,341
R01 · FY2025 · MH
Psychiatric Genomics Consortium for PTSD$204,864
R01 · FY2025 · MH
Psychiatric Genomics Consortium for PTSD$833,335
R01 · FY2024 · MH
Expanding Genetic Understanding of Depression, Anxiety, and their Treatments$706,877
R01 · FY2024 · MH
Psychiatric Genomics Consortium for PTSD$683,564
R01 · FY2023 · MH
Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder$548,095
R61 · FY2023 · AT
Psychiatric Genomics Consortium for PTSD$698,361
R01 · FY2022 · MH
Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder$551,121
R61 · FY2022 · AT
Target Engagement and Clinical Symptom Change with a FAAH Inhibitor for Posttraumatic Stress Disorder$1
R33 · FY2022 · MH · contact PI
Genomics of PTSD and Related Traits$0
I01 · FY2022 · VA
Psychiatric Genomics Consortium for PTSD$713,371
R01 · FY2021 · MH
Genomics of PTSD and Related Traits$0
I01 · FY2021 · VA
Psychiatric Genomics Consortium for PTSD$775,453
R01 · FY2020 · MH
Psychiatric Genomics Consortium for PTSD$190,611
R01 · FY2020 · MH
Genomics of PTSD and Related Traits$0
I01 · FY2020 · VA
Psychiatric Genomics Consortium for PTSD$835,607
R01 · FY2019 · MH
Genomics of PTSD and Related Traits$0
I01 · FY2019 · VA
A GEWIS Study of Smoking, Hazardous Drinking, and Other Health Risk Behaviors$148,321
R21 · FY2016 · AA
A GEWIS Study of Smoking, Hazardous Drinking, and Other Health Risk Behaviors$216,519
R21 · FY2015 · AA
A GEWIS Study of Smoking, Hazardous Drinking, and Other Health Risk Behaviors$32,741
R21 · FY2015 · AA
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army$10,000,000
U01 · FY2013 · MH
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army$10,000,000
U01 · FY2012 · MH
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army$10,000,000
U01 · FY2011 · MH
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army$4,998,274
U01 · FY2011 · MH
Neural Substrates of Anticipation and Interoception in Anxiety Disorders$309,734
R01 · FY2011 · MH · contact PI
Improving Outcomes and Understanding Response Heterogeneity in Anxiety Disorders$146,208
K24 · FY2011 · MH · contact PI
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army$9,997,086
U01 · FY2010 · MH
Neural Substrates of Anticipation and Interoception in Anxiety Disorders$312,863
R01 · FY2010 · MH · contact PI
Improving Outcomes and Understanding Response Heterogeneity in Anxiety Disorders$146,208
K24 · FY2010 · MH · contact PI
CALM: Improving Primary Care Anxiety Outcomes$380,636
U01 · FY2009 · MH · contact PI
Neural Substrates of Anticipation and Interoception in Anxiety Disorders$312,863
R01 · FY2009 · MH · contact PI
Improving Outcomes in Pharmacotherapy of Social Phobia$292,990
R01 · FY2009 · MH · contact PI
Improving Outcomes and Understanding Response Heterogeneity in Anxiety Disorders$135,856
K24 · FY2009 · MH · contact PI
CALM: Improving Primary Care Anxiety Outcomes$593,599
U01 · FY2008 · MH · contact PI
Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay$337,544
R01 · FY2008 · MH · contact PI
Neural Substrates of Anticipation and Interoception in Anxiety Disorders$312,863
R01 · FY2008 · MH · contact PI
Improving Outcomes in Pharmacotherapy of Social Phobia$292,987
R01 · FY2008 · MH · contact PI
Improving Outcomes and Understanding Response Heterogeneity in Anxiety Disorders$134,788
K24 · FY2008 · MH · contact PI
CALM: Improving Primary Care Anxiety Outcomes$796,539
U01 · FY2007 · MH · contact PI
Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay$337,544
R01 · FY2007 · MH · contact PI
Neural Substrates of Anticipation and Interoception in Anxiety Disorders$312,863
R01 · FY2007 · MH · contact PI
Improving Outcomes in Pharmacotherapy of Social Phobia$292,989
R01 · FY2007 · MH · contact PI
Improving Outcomes and Understanding Response Heterogeneity in Anxiety Disorders$133,750
K24 · FY2007 · MH · contact PI
CALM: Improving Primary Care Anxiety Outcomes$809,416
U01 · FY2006 · MH · contact PI
PharmacofMRI to Identify New Anxiolytics: A Human Bioassay$347,625
R01 · FY2006 · MH · contact PI
Improving Outcomes in Pharmacotherapy of Social Phobia$301,740
R01 · FY2006 · MH · contact PI
Neural Substrates of Decision-making in Anxiety$274,133
R01 · FY2006 · MH · contact PI
CALM: Improving Primary Care Anxiety Outcomes$766,885
U01 · FY2005 · MH
Improving Outcomes in Pharmacotherapy of Social Phobia$301,599
R01 · FY2005 · MH
Neural Substrates of Decision-making in Anxiety$280,811
R01 · FY2005 · MH
Improving Patient Outcomes in Anxiety Disorders$128,846
K24 · FY2005 · MH
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$3,053
M01 · FY2005 · RR
Neural Substrates of Decision-making in Anxiety$280,889
R01 · FY2004 · MH
Improving Patient Outcomes in Anxiety Disorders$128,846
K24 · FY2004 · MH
Paroxetine Treatment and Social Phobia: A PET Study$1,181
M01 · FY2004 · RR
Neural Substrates of Decision-making in Anxiety$249,465
R01 · FY2003 · MH
Preventing Psychiatric Sequelae of Traumatic Injury$156,938
R21 · FY2003 · MH
Improving Patient Outcomes in Anxiety Disorders$128,846
K24 · FY2003 · MH
IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE$307,960
R01 · FY2002 · MH
Preventing Psychiatric Sequelae of Traumatic Injury$156,938
R21 · FY2002 · MH
Improving Patient Outcomes in Anxiety Disorders$128,846
K24 · FY2002 · MH
IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE$54,196
R01 · FY2002 · MH
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2002 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2002 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2002 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2002 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2002 · RR
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2002 · RR
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2002 · RR
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2002 · RR
IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE$283,284
R01 · FY2001 · MH
Preventing Psychiatric Sequelae of Traumatic Injury$156,938
R21 · FY2001 · MH
Improving Patient Outcomes in Anxiety Disorders$128,777
K24 · FY2001 · MH
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2001 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2001 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2001 · RR
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2001 · RR
IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE$340,876
R01 · FY2000 · MH
IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE$29,216
R01 · FY2000 · MH
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2000 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2000 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2000 · RR
EFFECT OF TRYPTOPHAN FREE DRINK ON SOCIAL PHOBIC PATIENT$0
M01 · FY2000 · RR
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2000 · RR
GENETIC POLYMORPHISM AND HUMAN BEHAVIOR$0
M01 · FY2000 · RR